rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
2006-8-21
|
pubmed:abstractText |
The activating BRAF(V600E) mutation is the most common genetic alteration reported in papillary thyroid carcinoma (PTC). While some reports suggest the BRAF(V600E) mutation is associated with factors predicting a poor prognosis and recurrence, this remains a controversial issue.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0300-0664
|
pubmed:author |
pubmed-author:GongGyungyubG,
pubmed-author:HongSuck JoonSJ,
pubmed-author:KimJung MinJM,
pubmed-author:KimSang YoonSY,
pubmed-author:KimSeong ChulSC,
pubmed-author:KimTae YongTY,
pubmed-author:KimWon BaeWB,
pubmed-author:LeeSeungkooS,
pubmed-author:RheeYoon SooYS,
pubmed-author:ShongYoung KeeYK,
pubmed-author:SongJa YoungJY
|
pubmed:issnType |
Print
|
pubmed:volume |
65
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
364-8
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:16918957-Adult,
pubmed-meshheading:16918957-Carcinoma, Papillary,
pubmed-meshheading:16918957-Female,
pubmed-meshheading:16918957-Fluorodeoxyglucose F18,
pubmed-meshheading:16918957-Follow-Up Studies,
pubmed-meshheading:16918957-Humans,
pubmed-meshheading:16918957-Iodine Radioisotopes,
pubmed-meshheading:16918957-Male,
pubmed-meshheading:16918957-Middle Aged,
pubmed-meshheading:16918957-Multivariate Analysis,
pubmed-meshheading:16918957-Neoplasm Recurrence, Local,
pubmed-meshheading:16918957-Point Mutation,
pubmed-meshheading:16918957-Positron-Emission Tomography,
pubmed-meshheading:16918957-Prognosis,
pubmed-meshheading:16918957-Proportional Hazards Models,
pubmed-meshheading:16918957-Proto-Oncogene Proteins B-raf,
pubmed-meshheading:16918957-Radiopharmaceuticals,
pubmed-meshheading:16918957-Survival Analysis,
pubmed-meshheading:16918957-Thyroid Neoplasms,
pubmed-meshheading:16918957-Thyroidectomy
|
pubmed:year |
2006
|
pubmed:articleTitle |
The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
|
pubmed:affiliation |
Department of Internal Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|